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Summary
Until a few years ago, the mainstay of anti-platelet
therapy in patients with acute coronary syndrome
(ACS) was the combination of aspirin and clopido-
grel, a P2Y12 receptor inhibitor. However, current
clinical practice has now changed with the intro-
duction of ticagrelor, a more potent cardiovascular
drug than clopidogrel, without the limitations
related to clopidogrel therapy. In this review, we
provide a critical overview of ticagrelor in ACS,
highlight the results with ticagrelor in several sub-
groups of patients and discuss the future trials.
Introduction
The pathophysiology of acute coronary syndrome
(ACS) is characterized by the rupture of an athero-
sclerotic plaque within the coronary artery, with sub-
sequent platelet aggregation, thrombus formation
and ischaemia. Before platelets aggregate, they
must first be activated to express activated glycopro-
tein IIb/IIIa receptors on the cell surface. This activa-
tion is the result of stimulation from endogenous
platelet agonists, such as thromboxane A2 and ad-
enosine diphosphate (ADP). ADP activates platelets
by binding to P2Y12 receptors on the cell surface.
P2Y12 receptors are irreversibly antagonized by
clopidogrel, a P2Y12 receptor inhibitor. However,
clopidogrel therapy is flawed by several limitations;
this fact prompted the research for new drugs that
are able to overcome clopidogrel limitations.
In this review, we critically discuss the limitations
of clopidogrel therapy, the pharmacologic proper-
ties of the new cardiovascular drug ticagrelor, the
main findings of the randomized clinical studies
and of their subgroup analyses comparing ticagrelor
to clopidogrel therapy in the ACS setting.
Limitations of clopidogrel: why is
ticagrelor needed?
Clopidogrel as an anti-platelet agent has shown sev-
eral limitations. The first drawback is related to the
metabolism of clopidogrel, which is a prodrug
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requiring two-step activation involving several hep-
atic cytochrome P (CYP) isoenzymes to convert pro-
drug to the active metabolite. This results in a
delayed onset of action (6–8 h after a 300 mg load-
ing dose).
The second limitation of clopidogrel is related to
its irreversible binding to P2Y12 receptors, leading
to a gradual recovery of platelet function after drug
withdrawal; patients who need urgent surgical
revascularization are therefore, at increased risk
of bleeding within 5–7 days after cessation of clopi-
dogrel. In the Clopidogrel in Unstable angina to
prevent Recurrent Events trial (CURE) study,
among patients undergoing coronary artery bypass
grafting (CABG), bleeding tended to be more
common if CABG was performed within 5 days of
clopidogrel administration (8.5% with clopidogrel
vs. 5.7% with placebo).1
Despite clinical efficacy in a broad range of cor-
onary artery disease patients, pharmacodynamic
studies conducted in patients undergoing stenting
showed that clopidogrel therapy was associated
with variable and moderate platelet inhibition
(50% inhibition at steady state as demonstrated
by ex-vivo ADP-induced platelet aggregation) as
well.2,3 Additionally, moderate platelet inhibition
by clopidogrel is insufficient to suppress an increase
in ADP-induced platelet aggregation in the mid-
morning, in the period when myocardial infarction,
stroke and sudden cardiac death occur the most fre-
quently.4 The wide anti-platelet response variability
was characterized by a consistent percentage of pa-
tients (approximately one in three patients) exhibit-
ing high on-treatment platelet reactivity (HPR) that
was subsequently strongly linked to recurrent
ischaemic event occurrence in patients undergoing
percutaneous coronary intervention (PCI).5
Moreover, clopidogrel metabolism is influenced
by single nucleotide polymorphisms of genes
encoding cytochrome P450 isoenzymes. CYP2C19
is a particularly important isoenzyme that partici-
pates in the conversion to the active metabolite.6
Mega et al.7 showed that carriers of at least one
CYP2C19 reduced-function allele had relative re-
ductions of 32.4 and 9% in plasma concentration
of the active metabolite of clopidogrel and absolute
decrease in maximal platelet aggregation 4 h
after pretreatment with a 600 mg loading dose of
clopidogrel, respectively, as compared with
non-carriers. The pharmacokinetic and pharmaco-
dynamic effects of CYP2C19 reduced-function
allele on the response to clopidogrel were observed
after a loading dose and during the administration of
a maintenance dose. Carriers of a reduced-function
CYP2B6 allele also tended to have a lower
pharmacokinetic and pharmacodynamic response
to clopidogrel.
Finally, it is well known that multi-drug therapy
increases the risk of drug–drug interactions and this
holds true specifically for clopidogrel; clopidogrel, a
prodrug, requires hepatic CYP450 metabolic activa-
tion to produce the active metabolite that inhibits
the platelet P2Y12 receptor, decreasing platelet ac-
tivation and aggregation processes. Atorvastatin,
omeprazole and several other drugs have been
shown in pharmacodynamic studies to competi-
tively inhibit CYP activation of clopidogrel, eventu-
ally reducing clopidogrel responsiveness.8
Chemical properties of ticagrelor
Ticagrelor, a cyclopentyl-triazolo-pyrimidine acting
as an analogue of adenosine triphosphate (ATP),
constitutes a first non-thienopyridine direct platelet
P2Y12 receptor blocker.
Recognition of the fact that ATP competitively in-
hibits ADP-induced platelet aggregation encouraged
attempts to identify its stable and potent analogue.
Differences between the structures of ticagrelor and
ATP consist of inclusion of a nitrogen atom in the
purine-like moiety of ATP and omission of an
oxygen atom in the sugar-like moiety of the mol-
ecule.9 As a result of these changes, ticagrelor and
ATP exert opposed electrostatic properties: ticagre-
lor is lipophilic, whereas ATP is highly hydrophilic.
Ticagrelor possesses nanomolar affinity for the
P2Y12 receptor and remains highly selective for
this receptor when compared with other adenosine
receptors. As ticagrelor binds to the P2Y12 receptor
on a distinct site than thienopyridines, there is no
competition between them.
Another main difference between these platelet
ADP antagonists is related to the type of bond linking
ticagrelor or thienopyridines with the P2Y12 recep-
tor. Ticagrelor only forms a hydrogen bond and there
is no S-S covalent bond formation as with clopidogrel
or prasugrel.10 This could be the reason for the re-
versible anti-platelet effect played by ticagrelor since
hydrogen bonding is weaker than covalent bonding.
Pharmacology of ticagrelor
Pharmacological properties of ticagrelor vs. clopido-
grel are summarized in Table 1. Ticagrelor is rapidly
absorbed and has a half-life of 7–12 h, thus requiring
twice-daily dosing. Ticagrelor is directly active fol-
lowing oral administration. In addition, ticagrelor is
a reversible inhibitor, in contrast to clopidogrel,
which irreversibly blocks the P2Y12 receptor. Due
to the reversibility of ticagrelor binding to the P2Y12














receptor, its inhibitory effect is directly dependent
on plasma drug concentration. Although a fast
offset of ticagrelor action related to its reversibility
remains beneficial in patients requiring urgent
CABG, it theoretically could expose non-adherent
patients to increased risk for coronary artery stent
thrombosis if they missed one or two doses.
Therefore, similar to thienopyridines, it is crucial to
inform the patients undergoing coronary stenting
about to be strictly adherent to the anti-platelet ther-
apy with ticagrelor.
Ticagrelor has one known active metabolite
(AR-C124910XX), which is also rapidly formed.
The pharmacokinetics of ticagrelor and AR-
C124910XX are predictable, with dose-proportional
plasma concentrations after administration that are
stable at steady state. Ticagrelor and AR-
C124910XX are extensively metabolized into an
inactive metabolite (AR-C133913XX) and its glucor-
onide conjugate before being eliminated in urine.
Ticagrelor exerts its platelet-inhibitory effects
through an apparent antagonism of ADP activation
of the P2Y12 receptor, which in turn blocks its intra-
platelet signalling sequence. This antagonistic effect
is non-competitive, suggesting that there are distinct
binding sites on human P2Y12 receptors.
The pharmacokinetic data of the study of the
ONSET and OFFSET of antiplatelet effects compar-
ing ticagrelor, clopidogrel and placebo with aspirin
(ONSET-OFFSET)11 demonstrated that maximum
plasma concentration (Cmax), time to Cmax (tmax)
and area under the plasma concentration–time
curve from time 0–8 h (AUC0-8h) for ticagrelor
were 733 ng/ml, 2.0 h, 4130 ngh/ml, respectively;
and for AR-C124910XX were: 210 ng/ml, 2.1 h,
1325 ngh/ml, respectively.
In the response to ticagrelor in clopidogrel
nonresponders and responders and effect of switch-
ing therapies study (RESPOND),12 ticagrelor mean
Cmax and AUC0-8h following 2-week dosage
were comparable between clopidogrel responders
(724 ng/ml and 3983 ngh/ml) and non-responders
(764 ng/ml and 3986 ngh/ml). Pharmacokinetics
of ticagrelor were unaffected by prior clopidogrel
dosing; these results indicate that at current recom-
mended doses, ticagrelor therapy can provide sig-
nificant inhibition of platelet aggregation that is
similar in both clopidogrel responders and non-
responders.
Metabolism and potential drug
interactions
In in vitro experiments with human liver microsomes,
ticagrelor moderately inhibited CYP2C9 activity with
an IC50 of 10.5 M but little or no inhibition of
CYP1A2, CYP2B6, CYP2C8, CYP2C19, CYP2D6
and CYP2E1 activity was observed. Although ticagre-
lor exhibited a tendency for CYP2B6 and CYP2C9
induction, its potential to cause drug interactions
via the induction of these enzymes is low at a thera-
peutic dose. Finally, ticagrelor metabolism may be
inhibited when co-administrated with potent
CYP3A4/5 inhibitors such as ketaconalzole, dexame-
tahzone, rifampin, carbamazepine, phenytoin and
phenobarbital and co-administration of these drugs
are discouraged. Although there was increased tica-
grelor exposure with moderate CYP3A4 inhibitors
such as dilitiazem, amprenavir, fluconazole, erythro-
mycin and aprepitant, these agents can be co-admin-
istered with ticagrelor.
Off-target effects of ticagrelor
Unexpected mortality benefits present in the
PLATelet inhibition and patient Outcomes trial
(PLATO), a landmark phase III study comparing
ticagrelor with clopidogrel in a broad spectrum of
Table 1 Main pharmacologic characteristics of clopidogrel and ticagrelor
Clopidogrel Ticagrelor
Dose in ACS 600 mg loading dose, then 75 mg/die 180 mg loading dose, then 90 mg2/die
Route of administration Per os Per os
Mechanism of action Prodrug, irreversible Active drug, reversible
IPA (%) 40–60 85–95
Time to maximal IPA (h) 4–8 2–4
End of anti-platelet effect (days) 5–7 3–5
Half-life 11 days 7–12 h
Administration QD BID
Time to steady state (days) 3–7 2–3
Pharmacologic interactions Several, most important with omeprazol Rifampicin, ketoconazol, diltiazem
IPA (%), percentage of inhibition of platelet aggregation; QD, once daily; BID, twice daily.














ACS patients, despite only a moderate decrease in the
risk of subsequent myocardial infarction, led to a
speculation that advantages of ticagrelor therapy may
exceed its anti-platelet properties and may be, at least
partially, attributed to its off-target effects.13–16
Since P2Y12 receptors were identified on vascular
smooth muscle cells,17 we and others have demon-
strated in animal and human models that ticagrelor,
but not clopidogrel and prasugrel, prevents ADP-
induced vascular smooth muscle cells contrac-
tion.18,19 Lack of impact of thienopyridines on
vessel reactivity may be explained by high instability
of their active metabolites that do not reach the sys-
temic circulation in sufficient concentrations.18
Although the clinical relevance of the vasorelaxant
effect of ticagrelor is yet to be determined, coronary
vasospasm is generally accepted to frequently super-
impose atherosclerotic plaque instability and throm-
bus formation while ADP constitutes a powerful
platelet agonist being released from activated
platelets.
Additionally, investigating pleiotropic effects of
ticagrelor, other groups proved that ticagrelor not
only inhibits the uptake of adenosine by human
erythrocytes,20 but also induces release of ATP
from human erythrocytes, followed by its subse-
quent degradation to adenosine.21 The former
mechanism was also demonstrated to significantly
enhance the adenosine-induced increase in coron-
ary blood flow in a canine model.22 Furthermore,
Serebruany21 believes that ticagrelor may be trans-
formed to adenosine by degrading oxygenases and/
or cyclopropylcarbonyl radical fragmentation path-
ways Numerous features related to inhibition of
adenosine uptake by ticagrelor and probably chron-
ically increasing adenosine blood levels on ticagre-
lor therapy, such as promotion of pre-conditioning,
prevention of sudden cardiac death, reduction of
infarct size, inhibition of tumour growth, broncho-
constriction, neurocardiogenic syncope and upregu-
lation of purine metabolism, were postulated.21 Due
to its adenosine-like effects, ticagrelor has the poten-
tial to induce dyspnoea and to trigger ventricular
pauses. Similarly, transient elevations in uric acid
and creatinine concentrations were observed
during ticagrelor therapy.13 These adverse events
were usually mild and self-limiting in clinical
trials,13,23,24 but patients will need to be monitored
closely when starting ticagrelor therapy.
Randomized studies of ticagrelor vs.
clopidogrel in ACS
The randomized, double-blind, double-dummy
Dose confIrmation Study assessing anti-Platelet
Effects of AZD6140 vs. clopidogRel in non-St-seg-
ment Elevation myocardial infarction-2
(DISPERSE-2) trial25 evaluated the safety, tolerability
and initial efficacy of either ticagrelor or clopidogrel
added to aspirin in 990 patients with non-ST-
segment elevation ACS. The patients were rando-
mized in a 1:1:1 fashion to receive ticagrelor
90 mg twice a day, ticagrelor 180 mg twice a day
or a clopidogrel 300 mg loading dose plus 75 mg a
day for up to 12 weeks. Patients in the ticagrelor
group were further randomized to receive or not
receive the 270 mg loading dose of the drug. The
primary endpoint, Kaplan–Meier rate of
protocol-defined major or minor bleeding over 4
weeks, did not differ between the three groups
(9.8, 8.0 and 8.1%, respectively). Rates of major
bleeding were also similar (7.1, 5.1 and 6.9%,
respectively). Notably, the bleeding rates were not
different regardless of previous treatment with clopi-
dogrel, or administration of a loading dose of tica-
grelor or platelet glycoprotein IIb/IIIa inhibitors.
Asymptomatic ventricular pauses longer than 2.5 s
were more common with ticagrelor, particularly at
180 mg twice a day (5.5, 9.9 and 4.3%, respectively;
P = 0.58 and P = 0.01, respectively, vs. clopidogrel).
Remarkably, the study highlighted for the first time
that among patients undergoing CABG 1–5 days
after stopping the drug, treatment with ticagrelor as
opposed to clopidogrel was associated with a nu-
merically lower incidence of major bleeding, a find-
ing consistent with the reversible inhibition of the
P2Y12 receptor provided with AZD6140.
The ONSET/OFFSET study11 was a multi-centre,
randomized, double-blind, double-dummy,
parallel-group study of the onset and offset of anti-
platelet effects of ticagrelor (180 mg loading dose
and 90 mg daily maintenance dose) vs. high
loading-dose clopidogrel (600 mg loading dose fol-
lowed by 75 mg daily maintenance dose) in 123
patients with stable coronary artery disease.
Following the loading dose, a more rapid onset of
inhibition of platelet aggregation (IPA) was seen with
ticagrelor compared with clopidogrel either at
30 min (41 33% vs. 8 10%; P < 0.0001), 1 h
(79 25% vs. 23 26%; P < 0.0001) and 2 h
(88 15% vs. 38 32%; P < 0.0001). Higher IPA
for ticagrelor was also observed in the maintenance
therapy phase. A faster offset rate for IPA was
observed after the last dose of ticagrelor than for
clopidogrel from 4 to 72 h. In addition, ticagrelor
was shown to be associated with low prevalence
of high platelet reactivity at 2, 8 and 24 h, and 6
weeks compared with clopidogrel according to mul-
tiple established platelet function assays.
The RESPOND study12 was a randomized,
double-blind, double-dummy, crossover trial that














examined the use of ticagrelor in 98 patients with
stable coronary artery disease as a function of re-
sponsiveness to clopidogrel. Non-responsiveness to
clopidogrel was defined as a <10% absolute change
in 20mmol/l ADP-induced platelet aggregation be-
tween the baseline value and at 6–8 h after the
300 mg clopidogrel loading dose. In a two-way
crossover design, non-responders and responders
were randomly assigned to receive clopidogrel
(600 mg loading dose, then 75 mg once daily) or
ticagrelor (180 mg loading dose, then 90 mg twice
daily) for 14 days (period 1). Thereafter, all non-re-
sponders switched treatment, with half of the re-
sponders continuing the previous treatment, and
half switching treatment. The use of ticagrelor
among non-responders resulted in a 0.10, 0.30
and 0.50% decrease in platelet aggregation from
baseline in 100, 75 and 13% of the patients, respect-
ively. In addition, there was a significant
(P = 0.0001) decrease in platelet aggregation from
a mean 59% to 35% in patients who switched
from clopidogrel to ticagrelor and an increase in
platelet aggregation from mean 36% to 56% in pa-
tients switched from ticagrelor to clopidogrel. These
results indicated that the anti-platelet effect of tica-
grelor is consistent regardless of responsiveness to
clopidogrel, that ticagrelor may represent a logical
substitute for clopidogrel non-responders, and
that platelet inhibition in patients responsive to clo-
pidogrel may be significantly augmented by switch-
ing to ticagrelor without reduction in anti-platelet
effect.
Findings of the PLATO trial
The PLATO study13 was a multi-centre, randomized,
double-blind, phase III trial that compared ticagrelor
with clopidogrel. The study included over 18 000
patients who were admitted to hospital for an ACS,
with or without ST-segment elevation. Patients in the
ticagrelor group were given a loading dose of
180 mg, followed by a dose of 90 mg twice daily.
Patients in the clopidogrel group received a 300 mg
loading dose followed by 75 mg daily. Patients
undergoing PCI received an additional dose of
their study drug at the time of PCI: 300 mg clopido-
grel at the investigator’s discretion or 90 mg ticagre-
lor for patients who were undergoing PCI more than
24 h after randomization. In patients undergoing
CABG, it was recommended that the study drug be
withheld for 5 days in the clopidogrel group and for
24–72 h in the ticagrelor group. All patients received
75–100 mg aspirin daily. The primary efficacy end-
point was the composite of vascular death, myocar-
dial infarction (MI) and stroke, whereas the primary
safety endpoint included major bleedings defined
according to the study criteria.
The findings for the efficacy and safety endpoint
in the PLATO trial are summarized in Table 2. The
primary efficacy endpoint occurred significantly less
frequently in the ticagrelor group than in the clopi-
dogrel group [9.8 vs. 11.7% at 12 months; hazard
ratio (HR) 0.84, 95% confidence interval (95% CI)
0.77–0.92; P < 0.001]. This difference was apparent
as early as 30 days after the start of treatment and
was driven by statistically significant reductions in
both vascular death and MI (P < 0.01 for both).
The ticagrelor and clopidogrel groups did not
differ significantly with regard to the rates of major
bleeding as defined in the trial (11.6 and 11.2%,
respectively; P = 0.43). There was also no difference
in life-threatening or fatal bleeding (5.8% in each
group, P = 0.7). The two treatment groups also did
not differ significantly in the rates of CABG-related
major bleedings according to and the thrombolysis
in myocardial infarction (TIMI) criteria, despite the
fact that ticagrelor was only withheld for 24–72 h
before surgery, whereas clopidogrel was withheld
for 5 days. However, there was a higher rate of
non-CABG-related major bleeding with ticagrelor
compared with clopidogrel, according to the study
criteria (4.5 vs. 3.8%, P = 0.03) and TIMI criteria (2.8
vs. 2.2%, P = 0.03). There were also more episodes
of intra-cranial bleeding [26 (0.3%) vs. 14 (0.2%),
P = 0.06), including fatal intra-cranial bleeding [11
(0.1%) vs. 1 (0.01%), P = 0.02].
Based on the results of the PLATO study, treating
1000 patients who have ACS with ticagrelor instead
of clopidogrel would prevent 11 vascular deaths and
11 MIs at the cost of 6 non-CABG-related major
bleeding episodes. The overall results of this study
demonstrated that in patients who had ACS, treat-
ment with ticagrelor significantly reduced the pri-
mary endpoint of death from vascular causes, MI
and stroke, driven by a statistically significant reduc-
tion in death from vascular causes and MI, without
an increase in the rate of overall major bleeding, but
with an increase in the rate of non-procedure-
related bleeding.
Subgroups from the PLATO trial
Invasive management
Similar to the primary analysis, in ACS patients who
underwent an invasive strategy (72%, n = 13 408),
ticagrelor therapy was associated with a significant
reduction in the occurrence of the primary endpoint
(16% reduction, P = 0.0025), MI (20% reduction,
P = 0.0023), and all cause morality (19% reduction,
P = 0.0103).26 However, there was a non-significant














increase in stroke (8% increase, P = 0.646). In addi-
tion, there was a significant decrease in stent throm-
bosis (definite, definite or probable and total) that
was confined to patients treated with bare-metal
stents. Finally, the ticagrelor benefit remained sig-
nificant irrespective of the total clopidogrel loading
dose received either prior to randomization or at
24 h following study enrolment. Both primary effi-
cacy endpoint events and stent thrombosis were sig-
nificantly reduced by ticagrelor vs. clopidogrel
therapy whether subjects received a 5600 mg or a
<600 mg clopidogrel loading dose within 24 h pre-
or post-study enrolment.26
Non-invasive management
Of 18 624 participants in the PLATO trial, 5216
(28%) were specified as planned for non-invasive
management.27 The majority of these patients
(60%) were treated with only medical therapy
throughout the study period. They were older,
more frequently of female gender with diabetes
and hypertension than patients undergoing a
planned invasive strategy. The high risk profile of
conservatively treated patients is confirmed by the
higher overall mortality observed in such patients
than in those treated invasively (Figure 1).
Ticagrelor was very effective in reducing overall
mortality in such population with 2.1% absolute
risk reduction (6.1 vs. 8.2%, HR 0.75, 95% CI
0.61–0.93).27
Patients undergoing CABG
In the PLATO trial, 1899 patients (10%) underwent
CABG. Cardiac surgery was performed in 782 pa-
tients for whom an initial invasive strategy was
planned during admission. The recently published
results in this population however, refer to 1261 pa-
tients with the last intake of study drug within 7 days
before surgery.28 Median age was 64 years and 79%
were men. The primary endpoint was 10.6% in the
ticagrelor arm and 13.1% in the clopidogrel arm
patients (HR 0.84, 95% CI 0.60–1.16).
Cardiovascular death was significantly reduced in
ticagrelor-treated, as compared with clopidogrel-
treated patients (4.1 vs. 7.9%, P = 0.01), as well as
all-cause death (4.7 vs. 9.7%, P = 0.01).
Interestingly, the mortality reduction was evident
for patients with last intake of study drug from 2 to
5 days before surgery. Bleedings were similar in the
two groups, whatever definition was used.
Diabetes
In the pre-specified diabetes substudy of the PLATO
trial, based on admission levels of haemoglobin




































































































































































































































































































































































































































































































































































































































































12% reduction in the primary composite endpoint
occurrence (HR 0.88, 95% CI 0.76–1.03), an 18%
reduction in all-cause mortality (HR 0.82, 95% CI
0.66–1.01) and a 35% reduction in stent thrombosis
(HR 0.65, 95% CI 0.36–1.17) with no increase in
major bleedings (HR 0.95, 95% CI 0.81–1.12).
These benefits were seen irrespective of diabetic
status, insulin treatment and glycaemic control.
However, the reduction in primary end point occur-
rence was more pronounced in patients with a
HbA1c level above the median (HR 0.80, 95% CI
0.70–0.91).29
Renal insufficiency
Ticagrelor therapy was associated with 23% reduc-
tion in the primary endpoint (17.3 vs. 22.0%, HR
0.77, 95% CI 0.65–0.90) compared with clopidogrel
in patients with renal dysfunction (creatinine clear-
ance <60 ml/min, n = 3237), whereas there was only
a 10% relative risk reduction in patients with normal
renal function (7.9 vs. 8.9%, HR 0.90; 95% CI 0.79–
1.02).30 Similar to the primary analysis, in patients
with renal insufficiency, a 28% reduction in total
mortality (10.0 vs. 14.0%; HR 0.72, 95% CI 0.58–
0.89) but no significant differences in major bleed-
ing, fatal bleeding and non-CABG-related bleeding
were observed during ticagrelor therapy compared
with clopidogrel therapy.
Geographic region
Ruff et al.31 found a consistent reduction in is-
chaemic events, increased bleeding and a
favourable net clinical outcome with prasugrel,
another more potent anti-platelet agent, compared
with clopidogrel throughout the regions of the
world and in both developed and developing
countries, despite differences in patient demo-
graphics, procedural techniques, medical device
use, and adjunctive medications. On the contrary,
a significant interaction was observed between
treatment and region (P = 0.045) in the PLATO
trial, with less effect in North America than in
the rest of the world.32 Although a play of
chance could not be excluded, only aspirin
dose, that was higher in USA than in the other
countries, explained a substantial fraction of the
regional interaction. Moreover, high dosage
(5300 mg/day) was associated with a higher
hazard ratio for the primary endpoint with ticagre-
lor as compared with clopidogrel in both the USA
and the rest of the world. Although other pre-
randomization or post-randomization factors were
excluded as explanations, it must be noticed that
there were profound differences in patient charac-
teristics and modality of treatment between USA
and non-US countries.33 The great majority of en-
rolled patients in the USA were non-ST-elevation
MI (NSTEMI) patients, with a lower representa-
tion of ST-elevation MI (STEMI) than in non-US
countries. Concerns about the potential risk of
high dose aspirin and ticagrelor are addressed in
a Food and Drug Administration (FDA) boxed
warning for ticagrelor which states: ‘after initial
dosing, clinicians should use aspirin doses of
75–100 mg/day’.
Figure 1. All-cause death in the ticagrelor and clopidogrel arms of the PLATO trial. Percentages are Kaplan–Meier estimates
of the rate of the endpoint at 12 months. Mortality rates are reported in the overall population, in subgroups of patients
undergoing either planned invasive or conservative strategy, adapted from De Servi et al.33















Several unanswered questions regarding ticagrelor
therapy are addressed in the ongoing clinical
studies.
The PrEvention with ticaGrelor of secondAry
thrombotic events in high-riSk patients with prior
acUte coronary Syndrome-thrombolysis in myocar-
dial infarction 54 trial (PEGASUS-TIMI 54) investi-
gated the effectiveness of ticagrelor in comparison
with placebo on a background of aspirin therapy
in preventing cardiovascular events in 21 000 pa-
tients with history of MI between 1 and 3 years
ago with at least one additional risk factor, including
age 565 years old, diabetes requiring medication,
documented history of second prior myocardial
infarction (>1 year ago), angiographic evidence of
multi-vessel coronary artery disease and/or chronic,
non-end stage renal dysfunction.34 In this rando-
mized, double-blind, three-arm, parallel-group,
international, multi-centre study patients will be
assigned to either ticagrelor 60 or 90 mg twice
daily or placebo. The primary efficacy endpoint
for the Pegasus-TIMI 54 study is the composite of
cardiovascular death, non-fatal MI or non-fatal
stroke.
The Administration of Ticagrelor in the cardiac
catheterization Laboratory or in the Ambulance for
New sT-elevation myocardial Infarction to open the
Coronary artery trial (ATLANTIC) evaluates 30-day
efficacy and safety of pre-hospital vs. in-hospital ini-
tiation of ticagrelor therapy in 1770 patients with
ST-segment elevation MI planned for PCI.35
According to the study hypothesis, initiation of
ticagrelor as early as in the ambulance setting
leads to a rapid reperfusion of the infarct-related
artery therefore, facilitating PCI and optimizing
the outcome for the patient. The ATLANTIC trial is
designed as a randomized, parallel-group, double-
blind, placebo-controlled study. Based on the result
of randomization, patients receive a loading dose of
180 mg ticagrelor for the pre-hospital administration
and placebo for in-hospital administration or a pla-
cebo for pre-hospital administration and 180 mg
ticagrelor loading dose for in-hospital administra-
tion. All study participants continue on ticagrelor
90 mg twice daily (BID) and are followed in study
for 30 days post-randomization. TIMI flow grade 3
of MI culprit vessel at initial angiography and
ST-segment resolution up to pre-PCI 570% were
selected as primary study endpoints.
The Ticagrelor and Aspirin for the Prevention
of cardiovascular events after Coronary Artery
Bypass Surgery trial (TAP-CABG) is a randomized,
double-blind, parallel-group, single-centre study
aimed to assess safety and efficacy of ticagrelor
co-administered with aspirin for the prevention of
cardiovascular events after CABG.36 In this study,
244 patients will be assigned to receive either tica-
grelor 90 mg BID or placebo BID starting within 48 h
of surgery. The primary efficacy endpoint is the
composite of all-cause mortality, MI, stroke or
repeat revascularization within 1 year following
CABG, whereas secondary endpoints include the
individual endpoints of all-cause mortality, cardio-
vascular death, MI, stroke, repeat revascularization.
The most burning, still open, question is a direct
comparison of clinical outcomes in ACS patients
treated with either ticagrelor or prasugrel.
Furthermore, future studies are warranted to assess
the benefits of ticagrelor in older patients being at
high risk for bleeding and often under-represented in
clinical trials. Furthermore, the exact duration of
dual anti-platelet therapy with aspirin and ticagrelor
in patients undergoing invasive management with
coronary stent implantation and the optimal anti-co-
agulant regimens in combination with aspirin and
ticagrelor deserve further investigation as well.
Therapy with ticagrelor and bivalirudin in patients
treated with PCI may appear an appealing strategy
with maintained protection from ischaemic events
and potentially lower risk of bleeding complications
in comparison with the combination of clopidogrel,
unfractionated heparin and glycoprotein IIb/IIIa
inhibitor.
Optimal anti-platelet drug in ACS:
conclusive comments
New platelet adenosine P2Y12 antagonists have
successfully overcome many limitations of clopido-
grel and have further improved prognosis of ACS
patients. Therefore, both ticagrelor and prasugrel
were approved in Europe and in the USA and their
use in the setting of ACS is currently recommended
by international guidelines.37–39 Such recommenda-
tions correspond with the results of meta-analysis by
Navarese et al.40 assessing ischaemic and bleeding
complications with new, compared with standard,
ADP-antagonist regimens in the ACS setting.
Navarese and colleagues observed significant re-
ductions in mortality [odds ratio (OR) 0.87; 95%
CI 0.79–0.95; P = 0.002] (Figure 2), recurrent MI
(OR 0.80; 95% CI 0.74–0.87; P < 0.0001) and def-
inite in-stent thrombosis (OR 0.52; 95% CI 0.43–
0.63; P < 0.0001) attributed to therapy with new
oral anti-platelet regimens. In addition, there were
no significant differences in major bleeding compli-
cations with new platelet P2Y12 blockers as com-
pared with standard-dose clopidogrel (OR 1.06;
95% CI 0.96–1.17; P = 0.25).40








































































































































































































































































The favourable outcomes of ticagrelor in the
PLATO trial were seen in a wide range of patients,
including those managed invasively and conserva-
tively and those with and without ST-segment ele-
vation ACS. The ability of ticagrelor to reduce both
vascular death and MI is noteworthy, because nei-
ther high-dose clopidogrel nor prasugrel have
demonstrated vascular mortality reduction in the
management of ACS patients. Additionally, prasu-
grel is contra-indicated in patients with a history of
stroke or transient ischaemic attack, as there was an
increased risk of major bleeding in this population.
To sum up, ticagrelor (180 mg loading dose,
90 mg twice daily maintenance dose) is now recom-
mended for all patients at moderate-to-high risk of
ischaemic events, regardless of initial treatment
strategy and including those pre-treated with clopi-
dogrel, whereas prasugrel (60 mg loading dose,
10 mg daily maintenance dose) is advised only for
P2Y12-inhibitor-naive patients in whom coronary
anatomy is known and who are proceeding to PCI
unless there is a high risk of life-threatening bleeding
or other contraindications.
Acknowledgements
The present contribution is a project of Systematic
Investigation and Research on Interventions and
Outcomes (SIRIO)-MEDICINE, a group of senior sci-
entists and fellows collaborating world-wide to
pursue research and innovation in medicine.
Conflict of interest: E.P.N. and M.K. received honor-
aria from Astra Zeneca not related to the present
contribution.
References
1. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al.
Benefits and risks of the combination of clopidogrel and
aspirin in patients undergoing surgical revascularization for
non-ST-elevation acute coronary syndrome: The Clopidogrel
in Unstable angina to prevent Recurrent ischemic Events
(CURE) trial. Circulation 2004; 110:1202–8.
2. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel
for coronary stenting: response variability, drug resistance,
and the effect of pretreatment platelet reactivity. Circulation
2003; 107:2908–13.
3. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI,
Bhatt DL, Topol EJ. Variability in platelet responsiveness to
clopidogrel among 544 individuals. J Am Coll Cardiol 2005;
45:246–51.
4. Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J,
Stolarek W, Marciniak A, et al. Diurnal variation in platelet
inhibition by clopidogrel. Platelets 2011; 22:579–87.
5. Aradi D, Komócsi A, Vorobcsuk A, Rideg O, Tokés-Füzesi M,
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